We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| BioCryst Pharmaceuticals Inc | NASDAQ:BCRX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.02 | -0.45% | 4.46 | 4.45 | 4.55 | 4.67 | 4.42 | 4.59 | 2,737,156 | 00:44:58 |
From May 2022 to May 2024
By Colin Kellaher
BioCryst Pharmaceuticals Inc. on Wednesday said the U.S. Food and Drug Administration granted orphan-drug designation to BCX9250 for the treatment of fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder.
The Durham, N.C., pharmaceutical company said it aims to begin studies of the ALK-2 inhibitor in patients next year.
The FDA's orphan-drug program gives special status to drugs and biologics for diseases and disorders that affect fewer than 200,000 people in the U.S. and provides for an extended marketing exclusivity period against competition.
Fibrodysplasia ossificans progressiva is a severely disabling disorder characterized by the irregular formation of bone outside the normal skeleton.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 31, 2022 07:28 ET (11:28 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year BioCryst Pharmaceuticals Chart |
1 Month BioCryst Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
